important differences in baseline characteristics and treatment patterns between women and men with myocardial infarction (MI), but it is not well known how this relates to the observed differences in bleeding. Neither is it known whether, in addition to the observed gender difference in bleeding prevalence, there is a difference in prognostic impact of bleeding complications.
The aim of the current study was to assess the incidence of in-hospital bleeding in men and women. A second aim was to assess the gender specific impact of in-hospital bleeding complications on short-and long-term outcome.
Material and methods
We used data from the Swedish Web-system for Enhancement and Development of Evidence based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) (http://www.ucr.uu.se/swedeheart) register. We included 50,399 patients (36.6 % women) diagnosed with MI during the years 2006-2008, with at least one-year follow-up. The details of the register have been previously published. 8 SWEDEHEART is a national register where all coronary care units (CCUs) in Sweden register their patients including variables such as baseline characteristics, symptoms on arrival, ECGfindings, angiographic findings, medication at discharge, comorbidities, etc. The register also includes SCAAR (Swedish Coronary Angiography and Angioplasty register), SEPHIA (the register for secondary prevention and follow-up after myocardial infarctions) and the Swedish Heart Surgery Registry. To obtain detailed information on co-morbidities the database was linked to the National Patient Register, which collects all discharge diagnoses for patients admitted to hospitals in Sweden since 1987.
Outcomes
Bleeding complications during hospital stay were compared between women and men. Bleeding was defined according to a modified TIMI criteria 9 as fatal, intracranial, requiring transfusion or surgical intervention, or as a decrease in haemoglobin ⩾ 30 g/l (⩾ 40 g/l if occult). Coronary artery bypass graft (CABG)-associated bleeding was not included.
Mortality data were available for all patients and were obtained from the SWEDEHEART (in-hospital mortality) and the National Cause of Death Register (long-term mortality) respectively.
Ethics
In accordance with the ethical regulations for Swedish registries all patients were informed about their participation in the registry and had the right to refuse participation. The registry and the merging of registries were approved by the Swedish National Board of Health and Welfare, and the local ethical review board at Stockholm University (Dnr 2012/60-31/2).
Statistics
Continuous variables are presented as mean and standard deviation or median and interquartile range as appropriate. Categorical variables are presented as counts and percentages. Comparisons between groups were performed using chi-square tests for categorical variables and Student's t-test or Mann-Whitney for continuous variables, depending on whether the variable was normally distributed or not. p-values < 0.05 were considered to indicate statistical significance.
Crude and multivariable adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from logistic regression analyses in order to compare men and women with regard to in-hospital bleeding. Baseline variables with a significant association with bleeding on a 0.05 significance level in univariate tests were included in the model. Variables included in the CRUSADE bleeding score, known to be independently associated with bleeding in ACS patients, 10 as well as other variables deemed to be clinically important were forced into the model. Variables incorporated in the final model were: gender, age, active smoking, previous MI, previous stroke, hypertension, diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), heart failure, peripheral artery disease (PAD), cancer, estimated glomerular filtration rate (eGFR; MDRD formula) per 10 ml/min per 1.73 m 2 decrease, haemoglobin (Hb) per 1g/l decrease, heart rate per 10 beats/min increase, systolic blood pressure (<110, 110-180, >180 mmHg), Killip class on arrival, type of MI, coronary angiography and/or percutaneous coronary intervention (PCI) performed during index hospitalisation, therapy on arrival (aspirin, other platelet inhibitors, oral anticoagulants, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), statins, calcium-channel blockers (CCB), diuretics, medication during index hospitalisation (unfractionated heparin (UFH), fondaparinux, low molecular weight heparin (LMWH), inotropes, glycoprotein IIb/IIIa inhibitors (GPI)). Crude and multivariable ORs were presented with 95% CI.
To evaluate the impact of bleeding on mortality, Cox proportional hazard regression models were created for men and women separately, including the variables age, active smoking, comorbidities as above, therapy on arrival as above adding digitalis and long-acting nitrates, previous PCI, previous CABG, type of MI, coronary angiography and/or PCI performed during index hospitalisation, clinical parameters on admission as above, discharge medication (ACE inhibitors, ARB, beta-blockers, statins), in model 1. To explore the importance of antithrombotic use at discharge these were added into a second model. Crude and multivariable hazard ratios are presented with 95% CI. Unadjusted survival curves are presented.
All statistical analyses were performed with the SPSS Version 21.0 (PASW Statistics 21) software (SPSS, Inc., Chicago, Illinois, USA).
Results

Baseline characteristics and hospital care
Bleeding men were older, with lower body weight, higher heart rate, lower systolic blood pressure and haemoglobin, and more cardiac and non-cardiac comorbidities, compared with non-bleeding men.
In women, we found lower blood pressure, haemoglobin levels and eGFR among bleeders compared with nonbleeders. In contrast to in men, there were no differences in age, body weight or co-morbidity (except in PAD) between bleeding and non-bleeding women.
Comparing bleeding men with bleeding women we found men to be younger, heavier, with better kidney function, more often previous myocardial infarction, CABG surgery, stroke and cancer. (Table 1 ).
In men, coronary angiography and PCI were performed more often in non-bleeders than bleeders, whereas in women the opposite was found. In both men and women complications were more common among bleeders compared with non-bleeders, with the exception of mechanical complication in men and acute heart failure in women ( Table 2) .
In both genders, bleeders were less often prescribed platelet inhibitors compared with non-bleeders, especially dual antiplatelet therapy (DAPT). Non-bleeders were more often prescribed beta-blockers compared with bleeders in both genders. Non-bleeding men were also more often prescribed warfarin, statins and ACE-inhibitors compared with bleeders.
When comparing bleeding men with bleeding women, we found that during hospital stay men had more CABG surgery whereas women had more coronary angiography and PCI. Women were prescribed more aspirin, adenosine diphosphate (ADP) receptor inhibitors and DAPT at discharge ( Table 2 ).
Bleedings
The rate of bleeding during hospital stay was higher in women compared with men, 3.1% vs. 1.9%, (OR 1.71, 95% CI 1.53-1.92), p<0.001. After multivariable adjustment women still had 17% higher bleeding risk (OR 1.17, 95% CI 1.01-1.37). There was a significant interaction between bleeding, gender and type of MI, invasive treatment, renal function and age (all interaction p-values < 0.001). (Table 3 ).
Prognostic impact of bleeding
In-hospital and one-year mortality was higher in bleeders compared with non-bleeders, in both women and men (Table 4, Figure 1 ). After multivariate adjustment, one-year mortality was still significantly higher, bleeders versus non-bleeders, in men (OR 1.35, 95% CI 1.04-1.74) but not in women (OR 0.97, 95% CI 0.72-1.31), with a significant interaction test (p<0.001). When discharged antiplatelet/ anticoagulant medication was added to the multivariable adjustments, the effect of bleeding was further attenuated and no longer significant (Table 5 ). Also, in STEMI patients and in patients with an angiography performed, the adjusted risk increase associated with in-hospital bleeding was significant in men but not in women. Bleeding men had almost a doubled risk of long-term mortality compared with nonbleeding men in STEMI; whereas in NSTEMI the risk increase associated with bleeding was not statistically significant. Among age subgroups, the adjusted risk increase associated with bleeding was found only in the oldest group of men.
However, among the bleeders, there were no gender differences in mortality, neither in-hospital (11.6% vs. 12.5%, p=0.63) nor at one year (26.9% vs. 28.0%, p=0.69) ( Table 4 ).
Discussion
In 50,399 consecutive patients with MI we found a substantially higher in-hospital bleeding incidence in women compared with in men. The risk of in-hospital bleeding was 17% higher in women, even after extensive adjustment for differences in baseline characteristics. Both men and women with a bleeding complication had significantly higher short-and long-term mortality. However, after adjustment for baseline differences the prognostic impact of bleeding remained in men but not in women.
Most 6,11-13 but not all 14 prior studies of gender differences in short-term bleeding have shown higher incidence in women, also after adjustment for baseline differences. In the present trial the bleeding incidence was more than doubled in women as compared with men in the STEMI group, whereas in the NSTEMI group, the gender difference was less pronounced, and not statistically significant. In accordance with our data a recent publication from the HORIZON-AMI trial on STEMI patients showed twice the risk of bleeding in women compared with men. 15 In our study, after multivariable adjustment, there was no longer any difference in the NSTEMI group, whereas in the STEMI group women had almost 50% higher risk of bleeding, with a significant interaction test.
Higher bleeding incidence in women with STEMI may be due to the use of more potent antithrombotic drugs in STEMI. Female gender has been linked to an increased bleeding risk with antithrombotic agents including fibrinolytics, 16 UFH, (11) 71 (12) <0.001
75 (11) 75 (12) NS 72 (11) 69 (12) <0.001
<0.001
Weight in kg, mean (SD) 75 (16) 78 (16) <0.001
68 (14) 69 (14) NS 81 (16) 83 (14) 0.009
Systolic blood pressure, mmHg, mean (SD) (24) 81 (24) 0.002 83 (22) 84 (24) NS 83 (25) 79 (23) <0.001 NS Hemoglobin (g/L), mean (SD) 120 (25) 137 (17) <0.001 119 (22) 130 (16) <0.001 121 (28) 141 (17) <0.001 NS eGFR (mL/min/1.73m 2 ) mean (SD) 65 (29) 75 (28) <0.001
63 (29) 69 (28) <0.001 67 (30) 79 (28) <0 LMWH and GPIs, 17 partly attributable to excess dosing. 18 Another explanation for more bleeding in women with STEMI could be the high prevalence of PCI during the index hospital care compared with in NSTEMI as the difference in bleeding risk between the genders was even more obvious when stratifying by whether PCI was performed or not. In the group that underwent PCI (STEMI men 84%, NSTEMI men 52%, STEMI women 70%, NSTEMI women 34%), women had almost three times higher risk of bleeding compared with men, and after multivariate adjustment the risk was almost doubled. In contrast, in non-invasively treated patients, women tended to have lower risk of bleeding compared with men. Our findings are also consistent with recent data from the TRANSLATE-ACS study where women had 32% higher risk of bleeding during the first year after PCItreated MI, after multivariable adjustment. In the study, where all patients were treated with PCI, no difference between the STEMI and NSTEMI groups was found. 19 Coronary interventions have earlier been associated with more bleeding complications in women compared with in men. 20, 21 Interestingly, bleeding women in our study were more often invasively treated compared with those who did not bleed, whereas among men the opposite was found. Thus, bleeding in women may be due to the coronary angiography/PCI procedure per se, whereas in men, bleeding may be associated with higher age and comorbidity, possibly withholding them from an invasive strategy. This finding is in line with data from the PLATO trial, showing a more than two-fold risk for PCI-related bleeding in women (hazard ratio 2.25, 95% CI 1.42-3.56) whereas they actually had lower risk of spontaneous bleeding (hazard ratio 0.77, 95% CI 0.59-1.00). 22 Hence our data confirm, and with interaction testing further strengthen, earlier findings regarding higher bleeding incidence in women with STEMI and women treated invasively. We also observed that higher incidence of bleedings in women appeared to be restricted to patients with GFR ⩾ 60 ml/min per 1.73 m 2 , and to patients ⩽ 65 years. To our knowledge, this has not been shown before and deserves further studies. We had no data on whether radial or femoral access was used. Women may have been PCI-treated more often through femoral access than men as radial access is known to be more challenging in female patients because of the small size of the radial artery, radial artery spasm, and puncture failure. 23 Besides the access site there are several other possible mechanisms underlying the differences between men and women in bleeding such as lower body mass index, more co-morbidities, worse renal function and gender-specific pharmacology with difference in drug bioavailability and distribution influenced by the ratio of lean to fat tissue, 24 factors enhancing the risk of incorrect dosing of drugs in women. 7, 11 We found a substantially higher long-and short-term mortality among patients with in-hospital bleeding, both for men and women. Adverse impact of bleeding has been shown in numerous previous trials, but the mechanism for this association is not completely understood. The consequence of bleeding in ACS can be deleterious in several ways. Acute bleeding may be life-threatening because of its localisation (e.g. intracranial bleeding) and severe blood loss can perpetuate shock. In addition, bleeding leads to anaemia and transfusion of blood products, which promote inflammation. 25 Moreover, bleeding may result in cessation of antiplatelet and anticoagulant therapy, which increases the risk of recurrent ischaemic events such as stent thrombosis and MI. 26 However, perhaps most important, bleeding patients have been shown to differ from non-bleeding patients in several baseline characteristics with impact on outcome. Therefore, in order to understand the differences in outcome between bleeders and non-bleeders, it is of utmost importance to adjust for the observed baseline differences. In our study differences in baseline characteristics were obvious for men, with substantial differences between bleeders and non-bleeders, including higher age and more co-morbidity among the bleeders. Surprisingly, among women we found almost fewer differences in baseline characteristics between bleeders and non-bleeders.. To our knowledge, this is novel information.
A major and new finding in the present study was the observed gender difference in long-term prognostic impact of in-hospital bleeding, with a significant interaction test. After adjustment, bleeding men had 35% higher risk of mortality at one year compared with non-bleeders. When adding adjustment for antiplatelet/antithrombotic therapy at discharge the difference in risk attenuated and was not significant any longer, implying that withdrawal of this important post-MI therapy is one reason for the higher mortality among male bleeders. In contrast, after adjustment there was no association between bleeding and one-year mortality in women. Gender difference in short-term mortality (30 days) according to bleeding complications has been shown in NSTE ACS patients included in a randomised trial. 27 Our study extends this finding to long-term mortality in a much larger real-life population with both non-ST elevation (NSTE) ACS and STEMI, and our sub-group analyses indicate that there may be a difference according to type of ACS. The reason for a gender difference in impact of bleeding complications on long-term outcome is not obvious, but there are some possible explanations. First, previous trials have shown higher incidence of procedure related bleeding complications in women compared with men 22 and nonaccess site bleeding is a stronger correlate of mortality than access site bleeding. 22, [28] [29] [30] We cannot differentiate procedural from spontaneous bleedings in our cohort, although the above findings, with higher bleeding risk in women associated with coronary procedures, support that a larger proportion of the bleedings in women, compared with men, are procedure related. Second, given women's lower baseline haemoglobin value, there may be a greater attention among clinicians for bleeding in women and consequently transfusion treatment. A long-term consequence of transfusions, especially in patients with ACS, is still under debate. 31 Third, cessation of antithrombotic therapies among bleeders would be more dangerous in patients who have undergone stenting. Lower rates of antiplatelet treatment were seen in both male and female bleeders. It is well-known that among ACS patients men undergo PCI (including stenting) more often than women, partly due to the higher incidence of nonobstructive coronary artery disease in women, and why the consequences of lack of antiplatelet treatment may be more important in men. Lastly, a main explanation could be the observed pronounced difference in risk factors between bleeding and non-bleeding men, indicating that bleeding men are more comorbid and speculatively more frail compared with women.
In both men and women the risk of death appeared to be associated with withdrawal of antiplatelet/antithrombotic therapy, as the hazard ratios decreased when adjustment for these therapies was made. This was seen in both the STEMI and NSTEMI groups and is consistent with previous trials, where bleeding patients have been found to be treated less aggressively with antithrombotic medication, possibly leading to stent thrombosis, myocardial infarction and death. 26 Bleeding had a higher impact on long-term mortality for men compared with women in all studied subgroups.
Strengths and limitations
The current study includes a large number of MI patients, with a sufficient number to assure adequate statistical analyses. SWEDEHEART registry is a unique Swedish National Quality registry, with quality control and audit measures, covering all hospitals in Sweden treating MI patients. SWEDEHEART employs standardised criteria for defining MI as well as hospital outcomes. Long term outcome is complete in Sweden as the vital status of all citizens is registered in the Cause of Death Registry.
One limitation in this study is its non-randomised, observational nature. Thus multivariate analyses were used in order to reduce the bias inherent in this type of study and adjustment could be made only for registered variables. Variables that could be of importance about which we did not have information were, for example, catheterisation access site, bleeding location, and nature and type of bleeding. Neither did we have information on bleeding or ischaemic events including stent thrombosis after hospital discharge.
Conclusion
Women with MI have a higher rate of in-hospital bleedings than men, even after adjustment for baseline differences. Moreover, bleeding patients have substantially increased short-and long-term mortality compared with non-bleeding patients. However, after multivariable adjustment, in contrast to in men, there was no significant association between bleeding and one-year mortality in women.
